CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

Neuron

AU market earnings: Arcadium faces soft demand as neuron pharmaceuticals reaps royalty rewards

Arcadium reports a revenue dip to $255 million due to soft lithium demand, while Neuron Pharmaceuticals enjoys a royalty boost, signaling mixed market conditions and strategic adaptations in the face of global economic challenges.

2024-08-08T01:40:23+0100

Sandstone Insights: Neuren's FDA-approved Rett syndrome treatment driving growth

Neuren stands out with the only FDA-approved treatment for Rett syndrome. With high margins, strong operating leverage, and a promising clinical pipeline, Neuren is poised for substantial growth.

2024-06-18T01:55:57+0100

This website is owned and operated by IG Bank S.A. Registered address at 42 Rue du Rhone, 1204 Geneva, authorised and regulated by FINMA.

The information on this site is not directed at residents of the United States and Belgium, or any particular country outside Switzerland and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

TOP PARTNER

IG Group | Careers

Neuron

Article result template

AU market earnings: Arcadium faces soft demand as neuron pharmaceuticals reaps royalty rewards

Sandstone Insights: Neuren's FDA-approved Rett syndrome treatment driving growth

Markets

CFD trading

Trading platforms

Market insight

Contact us